These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11893366)

  • 1. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial.
    Jonkers IJ; Mohrschladt MF; Westendorp RG; van der Laarse A; Smelt AH
    Am J Med; 2002 Mar; 112(4):275-80. PubMed ID: 11893366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia.
    Krysiak R; Gdula-Dymek A; Okopien B
    Eur J Clin Pharmacol; 2011 Nov; 67(11):1109-17. PubMed ID: 21630032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated platelets in patients with severe hypertriglyceridemia: effects of triglyceride-lowering therapy.
    de Man FH; Nieuwland R; van der Laarse A; Romijn F; Smelt AH; Gevers Leuven JA; Sturk A
    Atherosclerosis; 2000 Oct; 152(2):407-14. PubMed ID: 10998469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia.
    Jonkers IJ; de Man FH; van der Laarse A; Frölich M; Gevers Leuven JA; Kamper AM; Blauw GJ; Smelt AH
    J Hypertens; 2001 Apr; 19(4):749-55. PubMed ID: 11330878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy.
    Mohrschladt MF; Weverling-Rijnsburger AW; de Man FH; Stoeken DJ; Sturk A; Smelt AH; Westendorp RG
    Atherosclerosis; 2000 Feb; 148(2):413-9. PubMed ID: 10657578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy.
    Jonkers IJ; Smelt AH; Hattori H; Scheek LM; van Gent T; de Man FH; van der Laarse A; van Tol A
    J Lipid Res; 2003 Aug; 44(8):1462-9. PubMed ID: 12754275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia.
    Jonkers IJ; Smelt AH; Princen HM; Kuipers F; Romijn JA; Boverhof R; Masclee AA; Stellaard F
    J Nutr; 2006 Apr; 136(4):987-91. PubMed ID: 16549462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia--a nuclear magnetic resonance study.
    Ikewaki K; Noma K; Tohyama J; Kido T; Mochizuki S
    Int J Cardiol; 2005 Jun; 101(3):441-7. PubMed ID: 15907413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normal oxidative stress and enhanced lipoprotein resistance to in vitro oxidation in hypertriglyceridemia: effects of bezafibrate therapy.
    de Man FH; Jonkers IJ; Schwedhelm E; Smelt AH; Onkenhout W; van Duyvenvoorde W; Buytenhek R; Leuven JA; Troost R; van Der Laarse A; Princen HM
    Arterioscler Thromb Vasc Biol; 2000 Nov; 20(11):2434-40. PubMed ID: 11073849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease.
    Jovinge S; Hamsten A; Tornvall P; Proudler A; Båvenholm P; Ericsson CG; Godsland I; de Faire U; Nilsson J
    Metabolism; 1998 Jan; 47(1):113-8. PubMed ID: 9440488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus.
    Yamaguchi T; Shirai K; Nagayama D; Nakamura S; Oka R; Tanaka S; Watanabe Y; Imamura H; Sato Y; Kawana H; Ohira M; Saiki A; Shimizu N; Tatsuno I
    J Atheroscler Thromb; 2019 Jul; 26(7):659-669. PubMed ID: 30584220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in the extrinsic pathway in hypertriglyceridemia do not cause a 'procoagulant state': effects of bezafibrate therapy.
    Jonkers IJ; de Man FH; van Tilburg NH; van der Laarse A; Sandset PM; Smelt AH; Bertina RM
    Blood Coagul Fibrinolysis; 2001 Dec; 12(8):705-12. PubMed ID: 11734672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL; Barradell LB; Plosker GL
    Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of bezafibrate on office, home and ambulatory blood pressure in hypertensive patients with dyslipidemia.
    Ohta Y; Kawano Y; Iwashima Y; Hayashi S; Yoshihara F; Nakamura S
    J Hum Hypertens; 2013 Jul; 27(7):417-20. PubMed ID: 23254592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
    Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry.
    Klempfner R; Erez A; Sagit BZ; Goldenberg I; Fisman E; Kopel E; Shlomo N; Israel A; Tenenbaum A
    Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):100-8. PubMed ID: 26957517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monocyte-suppressing effect of bezafibrate but not omega-3 fatty acids in patients with isolated hypertriglyceridaemia.
    Krysiak R; Gdula-Dymek A; Okopien B
    Basic Clin Pharmacol Toxicol; 2011 Jul; 109(1):23-9. PubMed ID: 21223512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil.
    Jonkers IJ; Smelt AH; Ledeboer M; Hollum ME; Biemond I; Kuipers F; Stellaard F; Boverhof R; Meinders AE; Lamers CH; Masclee AA
    Gut; 2003 Jan; 52(1):109-15. PubMed ID: 12477770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration.
    Totsuka M; Miyashita Y; Ito Y; Watanabe H; Murano T; Shirai K
    Atherosclerosis; 2000 Nov; 153(1):175-9. PubMed ID: 11058713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia.
    Saito Y; Yamada N; Shirai K; Sasaki J; Ebihara Y; Yanase T; Fox JC
    Atherosclerosis; 2007 Oct; 194(2):505-11. PubMed ID: 17223112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.